Navigation Links
1-Day Acuvue

Products1-Day Acuvue
Company Vistakon, a Johnson & Johnson Company
Item 1-Day Acuvue
Features Flexibility of full or part-time wear. Great for occasional use. Only daily disposable contact lenses with UV-blocking. No lens care or messy solutions required. The no-hassle healthiest way to wear lenses.
Description 1-Day Acuvue brand contact lenses offer the healthiest, most convenient way to wear contact lenses. There's no lens care or messy solutions required, just wear them one day and throw them away.
Info Vistakon, a Johnson & Johnson Company
Customer Service: (800) 843-2020
Web site: http://www.acuvue.com/

Related medicine products :

1. Acuvue Toric
2. Acuvue Bifocal
3. Acuvue 2 Colours
4. Acuvue2
5. Acuvue
6. Acuvue Advance with HYDRACLEAR
TAG: Day Acuvue
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products:
(Date:7/18/2008)...est weight loss yields significant health benefits...oalition -- a group of,experts on overweight and o...dia to reevaluate the way they report on weight lo...ed news coverage and editorial content that,leads ... dieters if they,lose an enormous amount of weight...
(Date:7/18/2008)...n Is Not What America Signed Up For, WASHINGTON, ... McCain,s,top economic advisor, Phil Gramm, echoed...s were "psychological" by saying Americans are in ... "nation of whiners." While McCain,distanced himse...ard as,McCain,s top economic adviser. Now, John Mc...
(Date:7/18/2008)... Behavior spanning the wide spectrum of the animal...rnational Behavioral Ecology Congress, hosted by t...n Aug. 10 -14, 2008, at Cornell University in Itha...e congress will feature plenary sessions on: , ...olutionary biology, Yale University, on "When Theo...
(Date:7/18/2008)...ren preventive antibiotics within one hour before ...sk for serious infections after the surgery, sugge...ugust issue of Pediatric Infectious Disease Journ...en who received antibiotics outside of the golden ...ely to develop serious infections at the surgery s...
Breaking Medicine News(10 mins):Health News:Medical Experts Call on Media to Rethink Coverage of Weight Loss 2Health News:Medical Experts Call on Media to Rethink Coverage of Weight Loss 3Health News:DNC: McCain Watch: The Economy 2Health News:DNC: McCain Watch: The Economy 3Health News:Averting postsurgical infections in kids: Give antibiotics within hour before first incision 2
...for resistance to food allergy has been identified...s currently no way to treat food allergy and the ... avoid certain foods and make sure they have injec...led by Dr Claudio Nicoletti at the Institute of Fo...
...ficials of DelSite Biotechnologies, Inc., a wholly... said the company's novel powder-based vaccine de...les that delay influenza pandemic preparedness whi...tions for the Control of Influenza VI Conference" ...
...nsylvania, Shire plc announced today that it has s...A) to the U.S. Food and Drug Administration (FDA) ...the treatment of Attention Deficit Hyperactivity D...cation is subject to a 10-month FDA review period....
...of Wales has proposed that artists are important t...Wales to help create better environments for pati... for all new hospital that is going to come up in ...order to ensure that the patients morale is booste...
Other Medicine News:Health News:Potential Target for Allergy Therapy 2Health News:DelSite Working Toward Solving Delivery of Influenza Vaccine in Pandemic Situations 2Health News:DelSite Working Toward Solving Delivery of Influenza Vaccine in Pandemic Situations 3Health News:VYVANSE(TM) Drug for the Treatment of ADHD in Adults 2Health News:Art in Hospitals to Enhance Patient Care 2
(Date:7/16/2008)... INTERNATIONAL AIDS SOCIETY AND KAISER FAMILY FOU...RAGE OF CONFERENCE FOR FREE, MENLO PARK, Calif., ...,International AIDS Society (IAS) and the Kaiser F...ess to the XVII International AIDS Conference,(AID...ugust 2008. Kaiser --,an independent operating fou...
(Date:7/16/2008)...Expanded Collaboration Supports Pivotal Phase 2b C...dress an Underlying Cause of Cystic Fibrosis -, S...- PTC,Therapeutics, Inc. (PTC) and Cy..., the nonprofit affiliate of the Cystic Fibrosis F...sting collaboration to support development,of PTC1...
(Date:7/15/2008)... - Company Reports Favorable Phase 1 RX-33...re/ -- Rib-X Pharmaceuticals, Inc.,("Rib-X" or the...n the,discovery and development of novel antibioti...tions, today announced the initiation of a Phase,2...tic compound RX-3341 in,the treatment of complicat...
(Date:7/15/2008)... BOSTON, July 15 /-Scimitar Equity, ...Board: ADXS), entitled, "The New Generation of,Can...e at website: http://www.scimitarequity.com ., B...is developing,proprietary Listeria monocytogenes (...d by Dr. Yvonne Paterson, Professor of Microbiolog...
Breaking Medicine Technology:Online Coverage of International AIDS Conference Includes Daily Webcasts, Podcasts and Interviews 2Online Coverage of International AIDS Conference Includes Daily Webcasts, Podcasts and Interviews 3Online Coverage of International AIDS Conference Includes Daily Webcasts, Podcasts and Interviews 4PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124 2PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124 3PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124 4Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections 2Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections 3Advaxis, Inc Initiation Coverage Review Issued By Scimitar Equity, LLC 2High Fat Diet Can Disrupt Bodys Clock 5652 1High Fat Diet Can Disrupt Bodys Clock 5652 2AIM Quoted Verona Pharma Progresses Anti Asthma Drug Studies 1705 1AIM Quoted Verona Pharma Progresses Anti Asthma Drug Studies 1705 2Frontiers in Cancer Prevention Research 1128 1New Study Reveals MRSA Bacteria Common Among Pigs and Farm Workers 5647 1New Study Reveals MRSA Bacteria Common Among Pigs and Farm Workers 5647 2New Study Reveals MRSA Bacteria Common Among Pigs and Farm Workers 5647 3
...ined Improvements in Blood Glucose,Control and Pro...Newswire-FirstCall/ -- Amylin,Pharmaceuticals, Inc...s from a study that showed BYETTA(R) (exenatide) i...els and progressive weight,loss through three and ... associated with improvements in cardiovascular ri...
...INESS WIRE)--June 25, 2007--Gilead,Sciences, Inc. ...ase III clinical trial evaluating the company,s on...oxil fumarate or tenofovir,DF) 300 mg as a potenti...nfection, met its primary efficacy endpoint. The d...y,s once-daily antiviral,drug Hepsera(R) (adefovir...
Other Medicine Technology:Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6